58027-55-7

Upstream product

• 65-45-2 salicylamide 
• 106-89-8 epichlorohydrin 

Downstream Products

• 58027-40-0 2-[2-Hydroxy-3-(2-phenylacetylamino-ethylamino)-propoxy]-benzamide 
• 58078-60-7 2-[2-Hydroxy-3-(1-methyl-2-phenylacetylamino-ethylamino)-propoxy]-benzamide 
• 58027-39-7 3-<(2-isobutyramidoethyl)amino>-1-(2-carbamoylphenoxy)propan-2-ol 
• 72742-63-3 2-[2-hydroxy-3-[[2-(3-indolyl)-1,1-dimethylethyl]amino]propoxy]benzamide 
• 34249-94-0 2-(2,3-epoxy-propoxy)-benzoic acid amide 
• 58027-38-6 1-o-carbamoylphenoxy-3-β-(3-phenylureido)ethylamino-2-propanol 
• 58027-41-1 2-{3-[2-((Z)-4-Amino-but-2-enoylamino)-ethylamino]-2-hydroxy-propoxy}-benzamide 
• 58027-71-7 2-[2-Hydroxy-3-(2-ureido-ethylamino)-propoxy]-benzamide 

Relevant academic research and scientific papers

Antihypertensive indole derivatives of phenoxypropanolamines with β-adrenergic receptor antagonist and vasodilating activity

A series of 25 aryloxypropanolamines containing the 3-indolyl-tert-butyl[i.e., 1,1-dimethyl-2-(1H-indol-3-yl)ethyl] or substituted 3-indolyl-tert-butyl moiety as the N substituent is reported. These compounds have been tested for antihypertensive activity in spontaneously hypertensive rats (SHR), β-adrenergic receptor antagonist action in conscious normotensive rats, vasodilating activity in ganglion-blocked rats with blood pressure maintained by angiotensin II infusion, and for intrinsic sympathomimetic action (ISA) in reserpinized rats. Some of the compounds exhibit antihypertensive activity in combination with β-adrenergic receptor antagonist and vasodilating action. The structure-activity relationships in these tests are discussed.